Publicacións (145) Publicacións de Pablo Aguiar Fernández

2024

  1. 18F-FDG positron emission tomography as a marker of disease activity and treatment response in ankylosing spondylitis and psoriatic arthritis

    Scientific Reports, Vol. 14, Núm. 1

  2. Biodistribution and pharmacokinetics of [89Zr]-anti-VEGF mAbs using PET in glioblastoma rat models

    International Journal of Pharmaceutics, Vol. 652

  3. Correction to: EANM perspectives for CZT SPECT in brain applications (European Journal of Nuclear Medicine and Molecular Imaging, (2024), 51, 12, (3680-3684), 10.1007/s00259-024-06788-6)

    European Journal of Nuclear Medicine and Molecular Imaging

  4. EANM perspectives for CZT SPECT in brain applications

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Neuroimaging biomarkers in the biological definition of Parkinson’s disease and dementia with Lewy bodies – EANM position on current state, unmet needs and future perspectives

    European Journal of Nuclear Medicine and Molecular Imaging

  6. Partial volume correction in longitudinal tau PET studies: is it really needed?

    NeuroImage, Vol. 289

  7. Perspectives of the European Association of Nuclear Medicine on the role of artificial intelligence (AI) in molecular brain imaging

    European Journal of Nuclear Medicine and Molecular Imaging

  8. Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

    International Journal of Pharmaceutics, Vol. 662

  9. Quantitative brain [18F]FDG PET beyond normal blood glucose levels

    NeuroImage, Vol. 300

2023

  1. A murine model of BSCL2-associated Celia's encephalopathy

    Neurobiology of Disease, Vol. 187

  2. Association of periodontitis with cognitive decline and its progression: Contribution of blood-based biomarkers of Alzheimer's disease to this relationship

    Journal of Clinical Periodontology, Vol. 50, Núm. 11, pp. 1444-1454

  3. EANM position paper: theranostics in brain tumours—the present and the future

    European Journal of Nuclear Medicine and Molecular Imaging

  4. FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

    JAMA neurology

  6. Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Candidate with Potential Application in Neuromuscular Disorders

    Biomedicines, Vol. 11, Núm. 2

  7. Prevalencia de dislipemia aterogénica, factores relacionados y grado de control lipídico en la población general de Galicia: Estudio GALIPEMIAS

    Clínica e investigación en arteriosclerosis, Vol. 35, Núm. 4, pp. 178-184

  8. Quantitative PET tracking of intra-articularly administered 89Zr-peptide-decorated nanoemulsions

    Journal of Controlled Release, Vol. 356, pp. 702-713

2022

  1. 18F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 4, pp. 1242-1253

  2. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence

    Pharmaceutics, Vol. 14, Núm. 10

  3. Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F]MC225 and PET

    Journal of Controlled Release, Vol. 347, pp. 500-507